UNLEASHING THE PROMISE OF T-CELL THERAPIES.

DISCOVER ATARA

Cutting-edge science. A fresh approach.

Atara is an allogeneic T-cell immunotherapy company. We're harnessing the natural biology of T cells—our body’s most effective weapon in fighting disease—to develop transformative therapies for patients with cancer and autoimmune conditions.

Off-the-shelf approach

Allogeneic T-cell therapies can be readily available for rapid delivery within days.

Scalable manufacturing

Efficient, robust process with the ability to produce over a thousand doses from one healthy donor.

Highly versatile platform

Potential application for a wide range of disease-causing viral and non-viral targets.

OUR TECHNOLOGY

We’re developing a pipeline of firsts.

Our investigational T-cell therapies target difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. We’re the first company ever to receive an approval for an allogeneic T-cell immunotherapy.

Our Pipeline

In the News

November 12, 2024
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress READ MORE
September 3, 2024
Atara Biotherapeutics Announces $36 Million Registered Direct Offering READ MORE
August 12, 2024
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update READ MORE

MORE NEWS

Dig deeper.

Explore patient stories, our clinical studies, or visit our investor hub for more information.